Takeda Pharmaceutical Co Earnings & Forecasts

Takeda Pharmaceutical Co (TAK) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

분기별 실적 서프라이즈 금액

회계 분기	보고된 날짜	실제 EPS	예상 EPS	놀라다 %
Q2	Oct 29, 2026	$0.48	$0.31	55.8 %
Q1	Jul 30, 2026	$0.48	$0.39	23.8 %
Q4	May 13, 2026	$0.28	$0.21	35.2 %
Q3	Jan 29, 2026	$0.48	$0.55	-13.6 %

Quarterly Revenue (Billions)

분기별 수익 깜짝 금액

회계 분기	보고된 날짜	실제 수익	예상 수익	놀라다 %
Q2	Oct 29, 2026	$7.46B	$7.19B	3.71 %
Q1	Jul 30, 2026	$7.65B	$7.06B	8.42 %
Q4	May 13, 2026	$6.98B	$7.05B	-1.02 %
Q3	Jan 29, 2026	$7.60B	$8.53B	-10.9 %

Takeda Pharmaceutical Co Guidance

Takeda Pharmaceutical Co (TAK)은 지난 10월 29, 2026에 fiscal year 2026의 실적 전망을 발표했습니다. 회사는 주당순이익을 $3.03 - $3.03 범위로 전망했으며, 이는 시장 컨센서스 EPS 추정치인 $1.57보다 높은 수치입니다. Takeda Pharmaceutical Co는 또한 해당 기간의 매출을 $29.52B - $29.52B 범위로 전망했습니다.

이전 가이던스와 비교하여 Takeda Pharmaceutical Co는 주당순이익(EPS) 전망치를 이전 범위인 상향 조정됨에서 $2.97 - $2.97로 상향 조정했습니다. 매출 측면에서는 회사가 매출 전망치를 이전 범위인 상향 조정됨에서 $29.15 - $29.15로 상향 조정했습니다.

Takeda Pharmaceutical Co은 16과 2월 2, 2023 사이에 10월 29, 2026개의 지침 업데이트를 발표했습니다. During this period, the company raised its outlook 7 times and lowered it 6 times, providing investors with insight into management's evolving expectations.

Recent Earnings Results

Metric	Q2 '26	Q1 '26	Q4 '25	Q3 '25
Earnings Per Share (Non-GAAP)
Estimate	$0.31	$0.39	$0.21	$0.55
Actual	$0.48	$0.48	$0.28	$0.47
Surprise	+55.8%	+23.8%	+35.2%	-13.6%
Revenue
Estimate	$7.19B	$7.06B	$7.05B	$8.53B
Actual	$7.46B	$7.65B	$6.98B	$7.60B
Surprise	+3.71%	+8.42%	-1.02%	-10.9%

Analyst Estimates — Forward PeriodsSource: Wall Street consensus

Metric	Q3 '26E	Q4 '26E	Q1 '27E
Earnings Per Share (Non-GAAP)
Consensus	$0.45	$0.28	$0.54
Revenue
Consensus	$7.65B	$7.22B	—

Earnings & Guidance News

Takeda Beats Earnings Forecasts and Hikes Outlook Despite Generic Overhang

Takeda Pharmaceutical (TAK) beats Q2 estimates and lifts fiscal 2026 guidance as pipeline growth and cost cuts balance off-patent Vyvanse losses.

Vandana Singh

PRO
Takeda Pharmaceutical Co Raises FY2026 Core EPS Guidance from JPY 472 to JPY 482; Raises FY2026 Revenue Guidance from JPY 4,640B to JPY 4,700B

Takeda Pharmaceutical Co (NYSE:TAK) Raises FY2026 Core EPS Guidance from JPY 472 to JPY 482; Raises FY2026 Revenue Guidance from JPY 4,640B to JPY 4,700B

Benzinga Newsdesk

PRO
Takeda Pharmaceutical Q2 Adj. EPS $0.48 Beats $0.31 Estimate, Sales $7.457B Beat $7.190B Estimate

Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.31 by 54.84 percent. This is a 20 percent increase over earnings of $0.40 per share from

Benzinga Newsdesk

PRO
Takeda Pharmaceutical Co Raises FY2026 GAAP EPS Guidance from JPY 104 to JPY 131

Takeda Pharmaceutical Co (NYSE:TAK) Raises FY2026 GAAP EPS Guidance from JPY 104 to JPY 131

Benzinga Newsdesk

PRO
CORRECTION: Takeda Pharmaceutical Co Affirms FY2026 Adj EPS Guidance of $3.01 vs $1.57 Est; Affirms FY2026 Sales Guidance of $29.585B vs $28.950B Est

Takeda Pharmaceutical Co (NYSE:TAK) affirms FY2026 Adj EPS guidance from $3.01 to $3.01 vs $1.57 analyst estimate. Affirms FY2026 sales outlook from $29.585 billion to $29.585 billion vs $28.950 billion estimate.

Benzinga Newsdesk

PRO
Takeda Pharmaceutical Co Affirms FY2026 GAAP EPS Guidance of $0.66; Affirms FY2026 GAAP Sales Guidance of $29.585B

Takeda Pharmaceutical Co (NYSE:TAK) affirms FY2026 GAAP EPS guidance from $0.66 to $0.66. Affirms FY2026 sales outlook from $29.585 billion to $29.585 billion.

Benzinga Newsdesk

Takeda Pharmaceutical Co Ltd

뉴스

파트너 / 기고자

벤징가 글로벌